169 related articles for article (PubMed ID: 34250421)
21. Underdiagnosis of Hereditary Breast Cancer: Are Genetic Testing Guidelines a Tool or an Obstacle?
Beitsch PD; Whitworth PW; Hughes K; Patel R; Rosen B; Compagnoni G; Baron P; Simmons R; Smith LA; Grady I; Kinney M; Coomer C; Barbosa K; Holmes DR; Brown E; Gold L; Clark P; Riley L; Lyons S; Ruiz A; Kahn S; MacDonald H; Curcio L; Hardwick MK; Yang S; Esplin ED; Nussbaum RL
J Clin Oncol; 2019 Feb; 37(6):453-460. PubMed ID: 30526229
[TBL] [Abstract][Full Text] [Related]
22. Probability of detecting germline BRCA1/2 pathogenic variants in histological subtypes of ovarian carcinoma. A meta-analysis.
Witjes VM; van Bommel MHD; Ligtenberg MJL; Vos JR; Mourits MJE; Ausems MGEM; de Hullu JA; Bosse T; Hoogerbrugge N
Gynecol Oncol; 2022 Jan; 164(1):221-230. PubMed ID: 34702566
[TBL] [Abstract][Full Text] [Related]
23. Gene-based Confirmatory Germline Testing Following Tumor-only Sequencing of Prostate Cancer.
Truong H; Breen K; Nandakumar S; Sjoberg DD; Kemel Y; Mehta N; Lenis AT; Reisz PA; Carruthers J; Benfante N; Joseph V; Khurram A; Gopalan A; Fine SW; Reuter VE; Vickers AJ; Birsoy O; Liu Y; Walsh M; Latham A; Mandelker D; Stadler ZK; Pietzak E; Ehdaie B; Touijer KA; Laudone VP; Slovin SF; Autio KA; Danila DC; Rathkopf DE; Eastham JA; Chen Y; Morris MJ; Offit K; Solit DB; Scher HI; Abida W; Robson ME; Carlo MI
Eur Urol; 2023 Jan; 83(1):29-38. PubMed ID: 36115772
[TBL] [Abstract][Full Text] [Related]
24. BRCA1/2 in non-mucinous epithelial ovarian cancer: tumour with or without germline testing?
Morgan RD; Burghel GJ; Flaum N; Bulman M; Smith P; Clamp AR; Hasan J; Mitchell CL; Salih Z; Woodward ER; Lalloo F; Crosbie EJ; Edmondson RJ; Wallace AJ; Jayson GC; Evans DGR
Br J Cancer; 2022 Jul; 127(1):163-167. PubMed ID: 35260807
[TBL] [Abstract][Full Text] [Related]
25. Germline genetic variants in men with prostate cancer and one or more additional cancers.
Pilié PG; Johnson AM; Hanson KL; Dayno ME; Kapron AL; Stoffel EM; Cooney KA
Cancer; 2017 Oct; 123(20):3925-3932. PubMed ID: 28657667
[TBL] [Abstract][Full Text] [Related]
26. Germline pathogenic variants in unselected Korean men with prostate cancer.
So MK; Ahn HK; Huh J; Kim KH
Investig Clin Urol; 2022 May; 63(3):294-300. PubMed ID: 35534218
[TBL] [Abstract][Full Text] [Related]
27. Clinical Utility of Universal Germline Genetic Testing for Patients With Breast Cancer.
Whitworth PW; Beitsch PD; Patel R; Rosen B; Compagnoni G; Baron PL; Simmons R; Brown EA; Gold L; Holmes D; Smith LA; Kinney M; Grady I; Clark P; Barbosa K; Lyons S; Riley L; Coomer C; Curcio L; Ruiz A; Khan S; MacDonald H; Hughes K; Hardwick MK; Heald B; Munro SB; Nielsen SM; Esplin ED
JAMA Netw Open; 2022 Sep; 5(9):e2232787. PubMed ID: 36136330
[TBL] [Abstract][Full Text] [Related]
28. Clinical Implications of Germline Testing in Newly Diagnosed Prostate Cancer.
Loeb S; Giri VN
Eur Urol Oncol; 2021 Feb; 4(1):1-9. PubMed ID: 33390340
[TBL] [Abstract][Full Text] [Related]
29. Predicting the likelihood of a
Morgan RD; Burghel GJ; Flaum N; Bulman M; Smith P; Clamp AR; Hasan J; Mitchell C; Salih Z; Woodward ER; Lalloo F; Shaw J; Desai S; Crosbie EJ; Edmondson RJ; Schlecht H; Wallace AJ; Jayson GC; Evans DGR
J Clin Pathol; 2023 Oct; 76(10):684-689. PubMed ID: 35738887
[TBL] [Abstract][Full Text] [Related]
30. Effect on Germline Mutation Rate in a High-Risk Chinese Breast Cancer Cohort after Compliance with The National Comprehensive Cancer Network (NCCN) 2023 v.1 Testing Criteria.
Kwong A; Ho CYS; Luk WP; Fung LH; Au CH; Ma ESK
Cancers (Basel); 2023 May; 15(9):. PubMed ID: 37174101
[TBL] [Abstract][Full Text] [Related]
31. Internet-Based Germline Genetic Testing for Men With Metastatic Prostate Cancer.
Cheng HH; Sokolova AO; Gulati R; Bowen D; Knerr SA; Klemfuss N; Grivas P; Hsieh A; Lee JK; Schweizer MT; Yezefski T; Zhou A; Yu EY; Nelson PS; Montgomery B
JCO Precis Oncol; 2023 Jan; 7():e2200104. PubMed ID: 36623239
[TBL] [Abstract][Full Text] [Related]
32. Detection of Pathogenic Variants With Germline Genetic Testing Using Deep Learning vs Standard Methods in Patients With Prostate Cancer and Melanoma.
AlDubayan SH; Conway JR; Camp SY; Witkowski L; Kofman E; Reardon B; Han S; Moore N; Elmarakeby H; Salari K; Choudhry H; Al-Rubaish AM; Al-Sulaiman AA; Al-Ali AK; Taylor-Weiner A; Van Allen EM
JAMA; 2020 Nov; 324(19):1957-1969. PubMed ID: 33201204
[TBL] [Abstract][Full Text] [Related]
33. Germline Pathogenic Variants and Genetic Counseling by Ancestry in Patients With Epithelial Ovarian Cancer.
Sia TY; Maio A; Kemel YM; Arora KS; Gordhandas SB; Kahn RM; Salo-Mullen EE; Sheehan MA; Tejada PR; Bandlamudi C; Zhou Q; Iasonos A; Grisham RN; O'Cearbhaill RE; Tew WP; Long Roche K; Zivanovic O; Sonoda Y; Gardner GJ; Chi DS; Latham AJ; Carlo MI; Murciano-Goroff YR; Will M; Walsh MF; Robson ME; Mandelker DL; Berger MF; Abu-Rustum NR; Brown CL; Offit K; Hamilton JG; Aghajanian C; Weigelt B; Stadler ZK; Liu YL
JCO Precis Oncol; 2023 Sep; 7():e2300137. PubMed ID: 37738546
[TBL] [Abstract][Full Text] [Related]
34. Genetic testing in prostate cancer management: Considerations informing primary care.
Giri VN; Morgan TM; Morris DS; Berchuck JE; Hyatt C; Taplin ME
CA Cancer J Clin; 2022 Jul; 72(4):360-371. PubMed ID: 35201622
[TBL] [Abstract][Full Text] [Related]
35. Utilization of genetic testing in men with advanced prostate cancer.
Aguiar JA; Li EV; Siddiqui MR; Soliman MA; Kumar SKSR; Schaeffer EM; Keeter MK; Brown CH; Szymaniak BM; Ross AE
Prostate; 2023 May; 83(6):516-523. PubMed ID: 36591888
[TBL] [Abstract][Full Text] [Related]
36. Germline Pathogenic Variants in the Ataxia Telangiectasia Mutated (
Hall MJ; Bernhisel R; Hughes E; Larson K; Rosenthal ET; Singh NA; Lancaster JM; Kurian AW
Cancer Prev Res (Phila); 2021 Apr; 14(4):433-440. PubMed ID: 33509806
[TBL] [Abstract][Full Text] [Related]
37. Diagnosing hereditary cancer predisposition in men with prostate cancer.
Pritzlaff M; Tian Y; Reineke P; Stuenkel AJ; Allen K; Gutierrez S; Jackson M; Dolinsky JS; LaDuca H; Xu J; Black MH; Helfand BT
Genet Med; 2020 Sep; 22(9):1517-1523. PubMed ID: 32439974
[TBL] [Abstract][Full Text] [Related]
38. Clinical Significance of Germline Pathogenic Variants among 51 Cancer Predisposition Genes in an Unselected Cohort of Italian Pancreatic Cancer Patients.
Puccini A; Ponzano M; Dalmasso B; Vanni I; Gandini A; Puglisi S; Borea R; Cremante M; Bruno W; Andreotti V; Allavena E; Martelli V; Catalano F; Grassi M; Iaia ML; Pirrone C; Pastorino A; Fornarini G; Sciallero S; Ghiorzo P; Pastorino L
Cancers (Basel); 2022 Sep; 14(18):. PubMed ID: 36139606
[TBL] [Abstract][Full Text] [Related]
39. Clinical Multigene Testing for Prostate Cancer.
Berro T; Barrett E; AlDubayan SH
Urol Clin North Am; 2021 Aug; 48(3):297-309. PubMed ID: 34210486
[TBL] [Abstract][Full Text] [Related]
40. Germline mutation prevalence in individuals with pancreatic cancer and a history of previous malignancy.
Dudley B; Karloski E; Monzon FA; Singhi AD; Lincoln SE; Bahary N; Brand RE
Cancer; 2018 Apr; 124(8):1691-1700. PubMed ID: 29360161
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
